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Tumor suppressor p53 
 the guardian of the genome
 essential for conserving genomic stability by preventing mutation
 its mutation and inactivation are highly related to all human cancers.(2)
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Function  of tumor suppressor p53 in cancers
 formation of p53 tetramers is needed to act as a transcription factor 
of several target genes.(3)
 posttranslational mechanisms abrogate it’s functions and stability(2)
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Function  of tumor suppressor p53 in cancers
missense mutations of the TP53 gene is the most common 
mechanism of it’s inactivation.
The majority of these mutations take place in the DNA 
binding domain (DBD).(3)
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Function  of tumor suppressor p53 in cancers
 the correlation of its inactivity and malignant development is 
highlighted .(2)
Cancers often deactivate p53, because: 
Trigger:    Cell growth arrest                    Impede:     Cell migration 
 Apoptosis                                                 Metabolism
 Autophagy                                              Angiogenesis
 Senescence 
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Function  of tumor suppressor p53 in cancers
trans dominant inhibition by mutant p53 causes impaired 
function.
the dominant negative effect of mutant p53  rise to a critical 
barrier to utilizing wt-p53 for cancer gene therapy(3)
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Function  of tumor suppressor p53 in cancers
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What is Gene Therapy?
one of the most rapidly developing fields of molecular medicine.
 It allows simple transfer of genetic methods aimed at correcting 
pathological processes into clinical practice(4)
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Type of gene therapy
Monogenic gene therapy
 Provides genes to encode for the production of a specific protein
Suicide gene therapy
 Provide ‘suicide’ genes to target cancer cells for destruction
Antisense gene therapy
 Provides a single stranded gene in an ’antisense’ orientation to block the production of harmful 
proteins.(6)
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Gene therapy targets
Germ line gene therapy
Somatic cell gene therapy(6)
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targeting synthetic
molecules 2014
2014
2008
2007
2006
Targeting p53-MDM2-MDMX Loop for Cancer Therapy
p53 as a target for the treatment of cancer
Mutant p53 targeting by the low molecular weight compound STIMA-1
Targeting the p53 Family for Cancer Therapy: ‘Big Brother’ Joins the Fight
Strategies for therapeutic targeting of the p53 pathway in cancer
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Targeting>>MDM2 and MDMX21
The p53-MDM2-MDMX feedback loop(1)22
Targeting p53-MDM2-MDMX Loop for Cancer Therapy(1)
strategies to identify and discover MDM2/MDMX-targeted inhibitors
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affinity-based assays for high throughput screenings
Screening of Phage Display Library
In Vitro Autoubiquitination and MDM2-Catalyzed p53 Ubiquitination Assay
Cell-Based Auto-ubiquitination Assay—
Fluorescence-Based Biosensor High Content Screening Assay
NMR-based and isothermal calorimetric approach
Affinity-based assays for high throughput screenings(1)
 surface plasmon resonance(SPR)
 fluorescence polarization(FP)
 fluorescence resonance energy transfer(FRET)
 fluorescence-correlation spectroscopy experiments(FCS)
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targeting RNA 2016
2016
2014
2003
Targeted p53 activation by saRNA suppresses human bladder cancer cells 
growth and metastasis
Overexpression of p53 activated by small activating RNA suppresses the 
growth of human prostate cancer cells
Overexpression of MicroRNA-30b Improves Adenovirus-Mediated p53 
Cancer Gene Therapy for Laryngeal  Carcinoma
Gene silencing by adenovirus-delivered siRNA
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Repurposing CRISPR/Cas9 for in situ functional assays
CRISPR-Cas9–based target validation for p53-reactivating model compounds
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile 
brain tumour modelling
CRISPR-mediated direct mutation of cancer genes in the mouse liver
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exosome 2014
2008
Interactions between Exosomes from Breast Cancer Cells
and Primary Mammary Epithelial Cells Leads to Generation of Reactive Oxygen 
Species Which Induce DNA Damage Response, Stabilization of p53 and Autophagy 
in Epithelial Cells
Exosome secretion, including the DNA damage-induced p53-dependent secretory 
pathway, is severely compromised in TSAP6/Steap3-null mice
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A patient with a large intrathoracic malignant schwannoma who showed a 
complete clinical response to rAd-p53-combined with radiotherapy.
Adenovirus-mediated p53 and ING4 gene co-transfer elicits synergistic 
antitumor effects through enhancement of p53 acetylation in breast cancer
p53 activated by AND gate genetic circuit under radiation and hypoxia for 
targeted cancer gene therapy
A combined lymphokine-activated killer (LAK) cell immunotherapy and 
adenovirus-p53 gene therapy for head and neck squamous cell carcinoma
44
P53 combination with other therapeutic
(Radiotherapy)
45
P53 combination with other therapeutic
(ING)
46
P53 combination with other therapeutic
(AND)
47
P53 combination with other therapeutic
(LAK)
48
investigations on P53 gene therapy
Type of gene 
therapy
Additional
therapeutic
Year
P53 
combinatio
n with other
therapeutic
siRNA
Penetrating 
peptide 11R
Ribosomal 
Protein L23 
2013
2013
2013
Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses 
the growth of cervical cancer in vitro and in vivo
Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R 
in gallbladder cancer cell lines in vitro and in vivo
Co-Transduction of Ribosomal Protein L23 Enhances the Therapeutic Efficacy of 
Adenoviral-Mediated P53 Gene Transfer in Human Gastric Cancer
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Vectors Viral
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1)adeno virus 
mediated
2)Retro virus
3)sv40 virus
2013
2013
1996
1994
1) Recombinant human adenovirus-p53 injection induced 
apoptosis in hepatocellular carcinoma cell lines mediated by 
p53-Fbxw7 pathway, which controls c-Myc and cyclin E
2) . Advances in adenovirus-mediated p53 cancer gene therapy.
1) Retrovirus−mediated wild−type P53 gene transfer to tumors of 
patients with lung cancer
1) Induction versus progression of brain tumor development: 
differential functions for the pRB- and p53-targeting domains of 
simian virus 40 T antigen
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liposome 2014
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A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer 
cells
p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome
p53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, 
Using Transferrin-Facilitated Lipofection Gene Delivery Strategy
Gene Therapy with P53 and a Fragment of Thrombospondin I Inhibits Human Breast Cancer in 
Vivo
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Dendrimers 2013
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Poly (amido amine) dendrimer silences the expression of epidermal growth factor 
receptor and p53 gene
in vitro
Efficient Delivery of p53 and Cytochrome C by Supramolecular Assembly of a 
Dendritic Multi-Domain Delivery System
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p53 gene therapy of human breast carcinoma: using a transferrin-modified silica 
nanoparticles
Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the 
MDM2 oncogene: Nanoparticle preparation characterization, in vitro and in vivo anti-
prostate cancer activity, and mechanisms of action
combination wt-p53 and microRNA 125b transfection in a genetically engineered lung 
cancer model using dual cd44/EFGR-targeting nanoparticles
Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells
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Conclusion points
1) in the near future, gene therapy will take its place alongside chemotherapy, radiotherapy, 
and surgery as one of the tools routinely available to help treat patients with cancer.
2) TP53 gene therapy has been tested in clinical trials in patients with lung cancer, head and 
neck cancer, prostate, cervical &breast cancer and other tumors and showed hopeful 
results.
3) studies have demonstrated a signiﬁcant clinical effect with stabilized tumor growth or 
even tumor regression in at least a fraction of the treated patients, and no major toxicity
4) additional clinical data is necessary to verify if these investigations  can effectively 
activate p53 and improve the clinical efficacy in patients carrying wild-type p53
75
References:
1)www.cancer.gov/publications/dictionaries/cancer-terms
2) Qi Zhang, Shelya X. Zeng, and Hua Targeting p53-MDM2-MDMX Loop for Cancer Therapy/Lu
3) Abood Okal1, Karina J. Matissek1,2, Stephan J. Matissek3, Robert Price1, Mohamed E. Salama4, Margit 
Maria Janát-Amsbury1,5,6, and Carol S. Lim1,6, Re-engineered p53 Activates Apoptosis In Vivo and Causes 
Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model
4) Zamyatnin AA Jr1Special Issue: Genome Editing and Gene Therapy
5) Jack A. Roth, Richard J. Cristiano/Gene Therapy for Cancer: What Have We Done and Where Are We Going?
6) Emery J, HayflickS. The challenge of integrating genetic medicine into primary care.Bmj. 
2001;322(7293):1027-30.
7)Victoria Portnoy,Vera Huang,Robert F. Place,Long-Cheng Li/Small RNA and transcriptional upregulation
8)Sujoy Dutta*, Case Warshall, Chirosree Bandyopadhyay, Dipanjan Dutta, Bala Chandran/Interactions 
between Exosomes from Breast Cancer Cells and Primary Mammary Epithelial Cells Leads to Generation of 
Reactive Oxygen Species Which Induce DNA Damage Response, Stabilization of p53 and Autophagy in Epithelial 
Cells
76
References:
 9) Minoru Nakase, Madoka Inui, Kenya Okumura, Takahiko Kamei, Shinnosuke Nakamura, and Toshiro 
Tagawa/p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome
 10) Alireza Nomani1, Shamileh Fouladdel2, Ismaeil Haririan3, Ramin Rahimnia2, Marika Ruponen4, Tarane
Gazori2, Ebrahim Azizi2/Poly (amido amine) dendrimer silences the expression of epidermal growth factor receptor 
and p53 gene  in vitro
 11) Miao Ding,1 Rong Li,2 Rong He,3 Xingyong Wang,3 Qijian Y1 and Weidong Wang4/p53 activated by AND 
gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy
 12) T Niidome and L Huang/Gene Therapy Progress and Prospects: Non viral vectors
 13) Abba Malina,1,6 John R. Mills,1,6,7 Regina Cencic,1 Yifei Yan,2 James Fraser,1 Laura M. Schippers,1 
Marile/Repurposing CRISPR/Cas9 for in situ functional assay
 14) Liang Li 1,4 and Binquan Wang /, Overexpression of MicroRNA-30b Improves  Adenovirus-Mediated p53 Cancer 
Gene Therapy for  Laryngeal Carcinoma 
 15) Marc Zuckermann1, Volker Hovestadt1, Christiane B. Knobbe-Thomsen2,3, Marc Zapatka1, Paul A. 
Northcott4, Kathrin Schramm1, Jelena Belic1, David T.W. Jones4, Barbara Tschida5, Branden Moriarity5, David 
Largaespada5, Martine F. Roussel6, Andrey Korshunov7,8, Guido Reifenberger2,3, Stefan M. Pﬁster4, Peter 
Lichter1, Daisuke Kawauchi4 & Jan Gronych1/Somatic CRISPR/Cas9-mediated tumour suppressor disruption 
enables versatile brain tumour modellin
77
References
 16) Lia,d,1, Yang Lia,d,1, Jiadi Hub,d, Bo Wanga,d, Lijing Zhaoa,d, Kun Jia,d, Baofeng Guoa,d, Di Yina,d, 
Yanwei Dua,d, Dennis J. Kopeckoc,d, Dhananjaya V. Kalvakolanudc,d, Xuejian Zhaoa,d, Deqi Xud,e,*, and 
Ling Zhanga/Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical 
cancer in vitro and in vivo
 17) Sukesh Voruganti1,*, Jiang-Jiang Qin1,*, Sushanta Sarkar1, Subhasree Nag1, Ismail A. Walbi1, Shu Wang3, 
Yuqing Zhao4, Wei Wang1,2, Ruiwen Zhang /Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural 
inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer 
activity, and mechanisms of action 
 18) One-step generation of p53 gene biallelic mutant Cynomolgus monkey via the CRISPR/Cas system
 19) JINGHAN WANG1,2*,  YONG YU2*,  ZI YAN1*,  ZHENLI HU3,  LINFANG LI1,   JIANG LI1,  
XIAOQING JIANG2  and  QIJUN QIAN1/Anticancer activity of oncolytic adenoviruses carrying p53 is augmented 
by 11R in gallbladder cancer cell lines in vitro and in vivo 
 20) YA-FEI ZHANG1,2*,  BI-CHENG ZHANG1*,  AN-RAN ZHANG2,  TING-TING WU1,  JIAN LIU1,   LI-
FANG YU1,  WEI-XING WANG1,  JIAN-FEI GAO1,  DIAN-CHUN FANG2  and  ZHI-GUO RAO1/Co-
transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in 
human gastric cancer 
78
References
 21) Qiangqiang ge1,* chenghe Wang2,* Yajun ruan1,* Zhong chen1 Jihong liu1 Zhangqun Ye Overexpression of 
p53 activated by small activating rna suppresses the growth of human prostate cancer cells
 22) Kangsheng Tu, Xin Zheng, Zhenyu Zhou, Chao Li, Jing Zhang, Jie Gao, Yingmin Yao, Qingguang
Liu/Recombinant Human Adenovirus-p53 Injection Induced Apoptosis in Hepatocellular Carcinoma Cell Lines 
Mediated by p53-Fbxw7 Pathway, Which Controls c-Myc and Cyclin E
 23) Changxian Shena, Andreas K. Bucka, Xiangwei Liua, Michael Winklerb, Sven N. Reskea /Gene silencing by 
adenovirus-delivered siRNA 
 24) Strategies for therapeutic targeting of the p53 pathway in cancer
 25)Helen S. Bell & Kevin M. Rya/Targeting the p53 Family for Cancer Therapy: ‘Big Brother’ Joins the Fight
 26) Zache,Pierre Hainaut, Jeremy M.R. Lamber Nina Ro¨kaeu, Jinfeng Shen, Jan Bergman, Klas G. Wiman, 
Vladimir J.N. Bykov /Mutant p53 targeting by the low molecular weightcompound STIMA-1Nicole 
 27) Wen Xue, Sidi Chen, Hao Yin, Tuomas Tammela, Thales Papagiannakopoulos, Nikhil S. Joshi, Wenxin
Cai, Gillian Yang, Roderick Bronson, Denise G. Crowley,Feng Zhang, Daniel G. Anderson, Phillip A. Sharp & 
Tyler Jacks/CRISPR-mediated direct mutation of cancer genes in the mouse liver
 28) • Michael Wanzel ,Jonas B Vischedyk ,Miriam P Gittler ,Niklas Gremke,Julia R Seiz ,Mirjam Hefter
,Magdalena Noack ,Rajkumar Savai ,Marco Mernberger / CRISPR-Cas9–based target validation for p53-
reactivating model compounds
79
References
 29) Lespagnol A1, Duflaut D, Beekman C, Blanc L, Fiucci G, Marine JC, Vidal M, Amson R, Telerman A. 
Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised 
in TSAP6/Steap3-null mice.
 30).Liu K1, Zhao J, Jiang H, Ma J, Tan J, Pei Y, Chen J. /A patient with a large intrathoracic malignant 
schwannoma who showed a complete clinical response to rAd-p53-combined with radiotherapy
 31) Wu J1, Zhu Y1, Xu C1, Xu H1, Zhou X1, Yang J2, Xie Y1, Tao M1/Adenovirus-mediated p53 and ING4 
gene co-transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
 32) Saito H1, Ando S2, Morishita N1, Lee KM3, Dator D4, Dy D5, Shigemura K6, Adhim Z7, Nibu K7, 
Fujisawa M7, Shirakawa T8. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-
p53 gene therapy for head and neck squamous cell carcinoma.
 33.Tazawa H1, Kagawa S, Fujiwara T. / Advances in adenovirus-mediated p53 cancer gene therapy
 34) J.A. Roth1, 10, D. Nguyen1, D.D. Lawrence2, B.L. Kemp3, C.H. Carrasco2, D.Z. Ferson4, W.K. Hong5, 
R. Komaki6, J.J. Lee7, J.C. Nesbitt1, K.M.W. Pisters5, J.B. Putnam1, R. Schea6, D.M. Shin5, G.L. Walsh1, 
M.M. Dolormente1, C.-I. Han1, F.D. Martin1, N. Yen1, K. Xu1, L.C. Stephens8, T.J. Mcdonnell9, T. 
Mukhopadhyay1 & D. Cai1/Retrovirus−mediated wild−type P53 gene transfer to tumors of patients with lung 
cancer.
80
References
 35) 1.M T Sáenz Robles,H Symonds, 3.J Chen  /Induction versus progression of brain tumor development: 
differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen.
 36)Masafumi Seki/Jun Iwakawa/Helen ChenG/Pi-Wan Cheng/Department of Biochemistry and Molecular 
Biology, College of Medicine and Eppley Cancer Center, University of Nebraska Medical Center, Omaha, 
NE 68198. p53 and PTEN/MMAC1/TEP1 Gene Therapy of Human Prostate PC-3 Carcinoma Xenograft, Using 
Transferrin-Facilitated Lipofection Gene Delivery Strategy
 37)M. Xu.D. KumarS.A. Stass A.J. Mixson1/Gene Therapy with P53 and a Fragment of Thrombospondin I 
Inhibits Human Breast Cancer in Vivo
 38) p53 gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles
 39)Sung Hee Choia, ,Su-Eon Jina, ,Mi-Kyung Leeb, ,Soo-Jeong Limc, ,Jeong-Sook Parkd, Byung-Gyu
Kime,,Woong Shick Ahnf, ,Chong-Kook Kima/Novel cationic solid lipid nanoparticles enhanced p53 gene 
transfer to lung cancer cells
 40) David Yuen Wah Ng,•Jörg Fahrer,•Yuzhou Wu,•Klaus Ei/Efficient Delivery of p53 and Cytochrome C by 
Supramolecular Assembly of a Dendritic Multi-Domain Delivery System
81
82
